Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LUMMICAR-2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- NCT03915184 ↗
- Active, not recruiting
- CARsgen Therapeutics Co., Ltd.
- Focused
We haven't built an HCP commentary report on LUMMICAR-2 (zevor-cel (CT053) in relapsed and/or refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LUMMICAR-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- zevor-cel
- Arms
- CAR-BCMA T Cells · Experimental
- Enrollment
- 105 (estimated)
- Primary outcomes
- Incidence of Treatment Related adverse events (AEs)
- Identification of Maximum Tolerated Dose (MTD)
- Objective response rate
- Sponsor
- CARsgen Therapeutics Co., Ltd.
- Start
- Sep 25, 2019
- Primary completion
- Dec 31, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT03915184 · updated Dec 19, 2023